Results 141 to 150 of about 1,515 (213)
Molecular Genetics &Genomic Medicine, Volume 14, Issue 6, June 2026.A case of MRX93 in a 1‐year‐and‐3‐month‐old girl was reported, in whom a heterozygous deletion from exon 21 to exon 30 in the BRWD3 gene occurred. We conducted a literature review to explore the clinical phenotypes and genetic characteristics of MRX93 in females. ABSTRACT Objective To report the clinical manifestations and genetic diagnosis of a female
Yang Xiu +4 more
wiley +1 more source
Lennox–Gastaut syndrome in a patient with biallelic TELO2 variants
Epileptic Disorders, Volume 28, Issue 3, Page 893-896, June 2026.
Melissa Odabassian, Kenneth A. Myers
wiley +1 more source
Neurourology and Urodynamics, Volume 45, Issue 5, Page 904-913, June 2026.ABSTRACT Introduction Management of overactive bladder (OAB) has a stepwise approach in adults and children. This does not account for individual patient variations, which may explain suboptimal outcomes in many patients. Distinct OAB profiles, based on patient characteristics, symptoms, urodynamic findings and imaging have been discussed in Part 1 ...
Michel Wyndaele +9 more
wiley +1 more source
, 1999 Objective Paroxysmal dyskinesias (PD) are currently classified in: paroxysmal kinesigenic and nonkinesigenic dyskinesia (PNKD), paroxysmal exertioninduced dyskinesia and paroxysmal hypnogenic dyskinesia. Recent studies described four families with benign
Tonon C. +4 more
core
Description, Articulation and Limitations in the Social Theory of Insurance
The British Journal of Sociology, Volume 77, Issue 3, Page 496-506, June 2026.ABSTRACT There have been surprisingly few sustained efforts to explain or theorise the role insurance plays in society. Even the most theoretically inflected insurance scholarship, emanating from governmentality and Actor Network Theory scholarship, tends to be grounded in empirical cases, set in particular periods and places, and it is often ...
Liz McFall
wiley +1 more source
THE RISK FACTORS IN RELAPSE OF FEBRILE CONVULSIONS
, 2016 The factors of risk in relapse of febrile convulsions have been studied: age, sex, perinatal anamnesis, heredity on febrile attacks, epilepsies, neurological status, the results in analysis (EEG, MRI of the head brain), the temperature, the type of the ...
A. F. Dolinina +2 more
core
Envisioning the Future of Work: From Ideas to Reforms
British Journal of Industrial Relations, Volume 64, Issue 2, Page 271-281, June 2026.ABSTRACT Two different theoretical perspectives concerning technology and the future of work are examined. One is linked to mainstream economics, whereas the other is associated with critical (‘post‐work’) discourse. Ideas about work—its nature and impacts on well‐being—matter in both perspectives.
David A. Spencer
wiley +1 more source
Developmental Medicine &Child Neurology, Volume 68, Issue 6, Page 857-863, June 2026.This multicenter retrospective study evaluated the use of intravenous immunoglobulin (IVIG) in 14 children with Dravet syndrome as a preventive strategy against febrile status epilepticus. Over a 6‐month period, IVIG was associated with a significant reduction in hospitalizations for febrile status epilepticus.
Romane Marc +9 more
wiley +1 more source
Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM
European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro +12 more
wiley +1 more source
European Journal of Haematology, Volume 116, Issue 6, Page 873-882, June 2026.ABSTRACT The GAIA‐CLL13 trial showed that venetoclax‐obinutuzumab (Ven‐O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment‐naïve (TN) CLL patients. However, their higher costs warrant a cost‐effectiveness evaluation.
Lars Holger Ehlers +6 more
wiley +1 more source